Global Adoptive Cellular Immunotherapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Adoptive Cellular Immunotherapy Market Overview

• 1.1 Product Overview and Scope of Adoptive Cellular Immunotherapy
• 1.2 Classification of Adoptive Cellular Immunotherapy by Types
  • 1.2.1 Global Adoptive Cellular Immunotherapy Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Adoptive Cellular Immunotherapy Revenue Market Share by Types in 2018
  • 1.2.3 TIL
  • 1.2.4 LAK
  • 1.2.5 CAR-T
  • 1.2.6 TCR-T
  • 1.2.7 CIK
  • 1.2.8 NK
  • 1.2.9 DC
  • 1.2.10 Other
• 1.3 Global Adoptive Cellular Immunotherapy Market by Application
  • 1.3.1 Global Adoptive Cellular Immunotherapy Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospital
  • 1.3.3 Cancer Hospital
  • 1.3.4 Centers for Disease Control and Prevention
  • 1.3.5 Rehabilitation Center
  • 1.3.6 Other
• 1.4 Global Adoptive Cellular Immunotherapy Market by Regions
  • 1.4.1 Global Adoptive Cellular Immunotherapy Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Adoptive Cellular Immunotherapy Status and Prospect (2014-2024)
• 1.5 Global Market Size of Adoptive Cellular Immunotherapy (2014-2024)

2 Manufacturers Profiles

• 2.1 Amgen Inc
  • 2.1.1 Business Overview
  • 2.1.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Amgen Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Autolus Therapeutics Plc
  • 2.2.1 Business Overview
  • 2.2.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Beijing Immunochina Medical Science & Technology Co Ltd
  • 2.3.1 Business Overview
  • 2.3.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Bellicum Pharmaceuticals Inc
  • 2.4.1 Business Overview
  • 2.4.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Bristol-Myers Squibb Co
  • 2.5.1 Business Overview
  • 2.5.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 bluebird bio Inc
  • 2.6.1 Business Overview
  • 2.6.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 bluebird bio Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 CARsgen Therapeutics Ltd
  • 2.7.1 Business Overview
  • 2.7.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Celgene Corp
  • 2.8.1 Business Overview
  • 2.8.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Celgene Corp Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Cell Medica Ltd
  • 2.9.1 Business Overview
  • 2.9.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Cell Medica Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Cellular Biomedicine Group Inc
  • 2.10.1 Business Overview
  • 2.10.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Celularity Inc
  • 2.11.1 Business Overview
  • 2.11.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Celularity Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Celyad SA
  • 2.12.1 Business Overview
  • 2.12.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Celyad SA Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Daiichi Sankyo Co Ltd
  • 2.13.1 Business Overview
  • 2.13.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Fosun Pharmaceutical AG
  • 2.14.1 Business Overview
  • 2.14.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Gilead Sciences Inc
  • 2.15.1 Business Overview
  • 2.15.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Gilead Sciences Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Guangzhou Anjie Biomedical Technology Co Ltd
  • 2.16.1 Business Overview
  • 2.16.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Hangzhou Converd Co Ltd
  • 2.17.1 Business Overview
  • 2.17.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Hebei Senlang Biotechnology Inc Ltd
  • 2.18.1 Business Overview
  • 2.18.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 HRAIN Biotechnology Co Ltd
  • 2.19.1 Business Overview
  • 2.19.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Juno Therapeutics Inc
  • 2.20.1 Business Overview
  • 2.20.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Juno Therapeutics Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Kite Pharma Inc
  • 2.21.1 Business Overview
  • 2.2.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Kite Pharma Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Nanjing Legend Biotech Co Ltd
  • 2.22.1 Business Overview
  • 2.22.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.23 NantKwest Inc
  • 2.23.1 Business Overview
  • 2.23.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.23.2.1 Product A
    • 2.23.2.2 Product B
  • 2.23.3 NantKwest Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.24 Nkarta Inc
  • 2.24.1 Business Overview
  • 2.24.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.24.2.1 Product A
    • 2.24.2.2 Product B
  • 2.24.3 Nkarta Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.25 Novartis AG
  • 2.25.1 Business Overview
  • 2.25.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.25.2.1 Product A
    • 2.25.2.2 Product B
  • 2.25.3 Novartis AG Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.26 Ono Pharmaceutical Co Ltd
  • 2.26.1 Business Overview
  • 2.26.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.26.2.1 Product A
    • 2.26.2.2 Product B
  • 2.26.3 Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • 2.27.1 Business Overview
  • 2.27.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.27.2.1 Product A
    • 2.27.2.2 Product B
  • 2.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.28 Sorrento Therapeutics Inc
  • 2.28.1 Business Overview
  • 2.28.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.28.2.1 Product A
    • 2.28.2.2 Product B
  • 2.28.3 Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.29 Takara Bio Inc
  • 2.29.1 Business Overview
  • 2.29.2 Adoptive Cellular Immunotherapy Type and Applications
    • 2.29.2.1 Product A
    • 2.29.2.2 Product B
  • 2.29.3 Takara Bio Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2017-2018)

3 Global Adoptive Cellular Immunotherapy Market Competition, by Players

• 3.1 Global Adoptive Cellular Immunotherapy Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Adoptive Cellular Immunotherapy Players Market Share
  • 3.2.2 Top 10 Adoptive Cellular Immunotherapy Players Market Share
• 3.3 Market Competition Trend

4 Global Adoptive Cellular Immunotherapy Market Size by Regions

• 4.1 Global Adoptive Cellular Immunotherapy Revenue and Market Share by Regions
• 4.2 North America Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 4.3 Europe Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 4.5 South America Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

5 North America Adoptive Cellular Immunotherapy Revenue by Countries

• 5.1 North America Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
• 5.2 USA Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 5.3 Canada Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

6 Europe Adoptive Cellular Immunotherapy Revenue by Countries

• 6.1 Europe Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
• 6.2 Germany Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 6.3 UK Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 6.4 France Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 6.5 Russia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 6.6 Italy Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Countries

• 7.1 Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
• 7.2 China Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 7.3 Japan Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 7.4 Korea Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 7.5 India Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

8 South America Adoptive Cellular Immunotherapy Revenue by Countries

• 8.1 South America Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
• 8.2 Brazil Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Adoptive Cellular Immunotherapy by Countries

• 9.1 Middle East and Africa Adoptive Cellular Immunotherapy Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 9.3 UAE Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Adoptive Cellular Immunotherapy Revenue and Growth Rate (2014-2019)

10 Global Adoptive Cellular Immunotherapy Market Segment by Type

• 10.1 Global Adoptive Cellular Immunotherapy Revenue and Market Share by Type (2014-2019)
• 10.2 Global Adoptive Cellular Immunotherapy Market Forecast by Type (2019-2024)
• 10.3 TIL Revenue Growth Rate (2014-2024)
• 10.4 LAK Revenue Growth Rate (2014-2024)
• 10.5 CAR-T Revenue Growth Rate (2014-2024)
• 10.6 TCR-T Revenue Growth Rate (2014-2024)
• 10.7 CIK Revenue Growth Rate (2014-2024)
• 10.8 NK Revenue Growth Rate (2014-2024)
• 10.9 DC Revenue Growth Rate (2014-2024)
• 10.10 Other Revenue Growth Rate (2014-2024)

11 Global Adoptive Cellular Immunotherapy Market Segment by Application

• 11.1 Global Adoptive Cellular Immunotherapy Revenue Market Share by Application (2014-2019)
• 11.2 Adoptive Cellular Immunotherapy Market Forecast by Application (2019-2024)
• 11.3 Hospital Revenue Growth (2014-2019)
• 11.4 Cancer Hospital Revenue Growth (2014-2019)
• 11.5 Centers for Disease Control and Prevention Revenue Growth (2014-2019)
• 11.6 Rehabilitation Center Revenue Growth (2014-2019)
• 11.7 Other Revenue Growth (2014-2019)

12 Global Adoptive Cellular Immunotherapy Market Size Forecast (2019-2024)

• 12.1 Global Adoptive Cellular Immunotherapy Market Size Forecast (2019-2024)
• 12.2 Global Adoptive Cellular Immunotherapy Market Forecast by Regions (2019-2024)
• 12.3 North America Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
• 12.4 Europe Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
• 12.6 South America Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Adoptive Cellular Immunotherapy Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology